<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2496">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518410</url>
  </required_header>
  <id_info>
    <org_study_id>A5401/ACTIV-2</org_study_id>
    <secondary_id>38742</secondary_id>
    <nct_id>NCT04518410</nct_id>
  </id_info>
  <brief_title>ACTIV-2: A Study for Outpatients With COVID-19</brief_title>
  <official_title>Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brii Biosciences Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sagent Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Synairgen Research Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug studies often look at the effect one or two drugs have on a medical condition, and&#xD;
      involve one company. There is currently an urgent need for one study to efficiently test&#xD;
      multiple drugs from more than one company, in people who have tested positive for COVID-19&#xD;
      but who do not currently need hospitalization. This could help prevent disease progression to&#xD;
      more serious symptoms and complications, and spread of COVID-19 in the community.&#xD;
&#xD;
      This study looks at the safety and effectiveness of different drugs in treating COVID-19 in&#xD;
      outpatients. Participants in the study will be treated with either a study drug or with&#xD;
      placebo and will have 28 days of intensive follow-up following study drug administration,&#xD;
      followed by limited follow-up through 24 weeks. Study visits may be required after week 24&#xD;
      depending on the study agent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a master protocol to evaluate the safety and efficacy of multiple investigational&#xD;
      agents aimed at modifying the host immune response to SARS-CoV-2 infection, or directly&#xD;
      enhancing viral control in order to limit disease progression.&#xD;
&#xD;
      The study includes both infused and non-infused agents. For infused agents, enrollment will&#xD;
      be restricted to participants at higher risk of progression to severe COVID-19. Non-infused&#xD;
      agents will be open to participants at both &quot;higher&quot; and &quot;lower&quot; risk of progression to&#xD;
      severe COVID-19.&#xD;
&#xD;
      For infused agents, the study begins with a phase II evaluation, followed by a transition&#xD;
      into a larger Phase III evaluation for promising agents. Phase III evaluation is a&#xD;
      continuation of the phase II trial for agents that meet study-defined criteria for further&#xD;
      evaluation and for which sufficient investigational agent is available. An infused agent may&#xD;
      also enter directly into phase III evaluation based on Trial Oversight Committee (TOC)&#xD;
      assessments.&#xD;
&#xD;
      For non-infused agents, the same phase II study will be undertaken as for infused agents.&#xD;
      Following design of the phase III evaluation for non-infused agents in a subsequent version&#xD;
      or amendment of the protocol these may also enter directly into phase III based on TOC&#xD;
      assessments.&#xD;
&#xD;
      Investigational agents will be selected by the TOC for phase II evaluation based on the&#xD;
      presence of in vitro data demonstrating promise as anti-SARS-CoV-2 therapeutics in&#xD;
      pre-clinical testing, and for which there are suitable pharmacokinetics and safety data from&#xD;
      phase I testing, or through clinical or research testing for a different indication, and&#xD;
      agent availability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Unblinded data will be provided to the Data and Safety Monitoring Board for interim analyses. Unblinded Day 28 data will also be provided to a small group of people from the company who owns the investigational agent, to assist the company in deciding if the agent should move into phase 3 evaluation; or in choosing a dose of their agent to move into phase 3 evaluation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of targeted clinical COVID-19 symptoms (Phase 2)</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Symptoms: Fever or feeling feverish; cough, shortness of breath or difficulty breathing at rest or with activity; sore throat; body pain or muscle pain/aches; fatigue; headache, chills, nasal obstruction or congestion; nasal discharge (runny nose); nausea or vomiting; and diarrhea. Each symptom is scored daily by the participant as absent (score 0), mild (1), moderate (2) or severe (3)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of SARS-CoV-2 RNA (Phase 2)</measure>
    <time_frame>Day 3</time_frame>
    <description>Measured as quantification (&lt;LLoQ versus ≥LLoQ ) from site-collected NP (nasopharyngeal) swabs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of SARS-CoV-2 RNA (Phase 2)</measure>
    <time_frame>Day 7</time_frame>
    <description>Measured as quantification (&lt;LLoQ versus ≥LLoQ ) from site-collected NP (nasopharyngeal) swabs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of SARS-CoV-2 RNA (Phase 2)</measure>
    <time_frame>Day 14</time_frame>
    <description>Measured as quantification (&lt;LLoQ versus ≥LLoQ ) from site-collected NP (nasopharyngeal) swabs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of SARS-CoV-2 RNA (Phase 2)</measure>
    <time_frame>Day 28</time_frame>
    <description>Measured as quantification (&lt;LLoQ versus ≥LLoQ ) from site-collected NP (nasopharyngeal) swabs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of new adverse event (AE) ≥ Grade 3 (Phase 2)</measure>
    <time_frame>Thru Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence of death from any cause or hospitalization (Phase 3)</measure>
    <time_frame>Thru Day 28</time_frame>
    <description>Hospitalization defined as ≥24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address medical needs of those with severe COVID-19</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with new adverse event (AE) ≥ Grade 3 (Phase 3)</measure>
    <time_frame>Thru Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of targeted clinical COVID-19 symptoms (Phase 3)</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Symptoms: Fever or feeling feverish; cough, shortness of breath or difficulty breathing at rest or with activity; sore throat; body pain or muscle pain/aches; fatigue; headache, chills, nasal obstruction or congestion; nasal discharge (runny nose); nausea or vomiting; and diarrhea. Each symptom is scored daily by the participant as absent (score 0), mild (1), moderate (2) or severe (3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of death from any cause or hospitalization (Phase 2)</measure>
    <time_frame>Thru Day 28</time_frame>
    <description>Hospitalization defined as ≥24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address medical needs of those with severe COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of SARS-CoV-2 RNA from participant-collected nasal swabs (Phases 2 and 3)</measure>
    <time_frame>Thru Day 28</time_frame>
    <description>Measured as quantification (&lt;LLoQ versus ≥LLoQ ) and level from participant-collected nasal swabs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 symptom severity ranking (Phases 2 and 3)</measure>
    <time_frame>From Day 0 thru Day 28</time_frame>
    <description>Based on symptom severity scores. Symptoms: Fever or feeling feverish; cough, shortness of breath or difficulty breathing at rest or with activity; sore throat; body pain or muscle pain/aches; fatigue; headache, chills, nasal obstruction or congestion; nasal discharge (runny nose); nausea or vomiting; and diarrhea. Each symptom is scored daily by the participant as absent (score 0), mild (1), moderate (2) or severe (3). For participants who are alive at 28 days and not previously hospitalized, the severity ranking will be based on the area under the curve (AUC) of the symptom score associated with COVID-19 disease over time. Participants hospitalized or who die during follow-up through 28 days will be ranked as worse than those alive and never hospitalized as follows (in worsening rank order): alive and not hospitalized at 28 days; hospitalized but alive at 28 days; and died at or before 28 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with ≥1 worsening symptom of COVID-19 (Phases 2 and 3)</measure>
    <time_frame>Thru Day 28</time_frame>
    <description>Progression of one or more COVID-19-associated symptoms to a worse status than recorded in study diary at study entry, prior to start of investigational product or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to self-reported return to usual (pre-COVID-19) health (Phases 2 and 3)</measure>
    <time_frame>Thru Day 28</time_frame>
    <description>As recorded in participant's study diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of death from any cause or hospitalization (Phases 2 and 3)</measure>
    <time_frame>Day 0 thru Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation level (Phase 2)</measure>
    <time_frame>Thru Day 28</time_frame>
    <description>Measured by pulse oximeter and categorized as &lt;96% versus ≥96%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of SARS-CoV-2 RNA from site-collected nasal swabs (Phases 2 and 3)</measure>
    <time_frame>Thru Day 28</time_frame>
    <description>Measured by area under the curve (AUC) and above assay lower limit of quantification of quantitative SARS-CoV-2 RNA over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of SARS-CoV-2 RNA from participant-collected nasal swabs (Phases 2 and 3)</measure>
    <time_frame>Thru Day 28</time_frame>
    <description>Measured by area under the curve (AUC) and above assay lower limit of quantification of quantitative SARS-CoV-2 RNA over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new adverse event (AE) ≥ Grade 2 (Phase 2)</measure>
    <time_frame>Thru Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new adverse event (AE) ≥ Grade 2 (Phase 2)</measure>
    <time_frame>Thru Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new adverse event (AE) ≥ Grade 3 (Phase 3)</measure>
    <time_frame>Thru Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level (quantitative) of SARS-CoV-2 RNA from site-collected NP swabs (Phase 2)</measure>
    <time_frame>Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level (quantitative) of SARS-CoV-2 RNA from site-collected NP swabs (Phase 2)</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level (quantitative) of SARS-CoV-2 RNA from site-collected NP swabs (Phase 2)</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level (quantitative) of SARS-CoV-2 RNA from site-collected NP swabs (Phase 2)</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Coronavirus</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Bamlanivimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BRII-196/BRII-198</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD7442 (IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and use the same method of administration. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SNG001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by inhalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Inhaled solution)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and administered in the same way. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD7442 (IM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by IM injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (IM)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and administered in the same way. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Camostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered as oral tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (oral tablets)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and administered in the same way. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C135-LS + C144-LS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered as subcutaneous (SC) injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (SC injections)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and administered in the same way. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bamlanivimab</intervention_name>
    <description>7000 mg or 700 mg (Phase 2), 700 mg (Phase 3). Administered by single IV infusion. Phases 2 and 3 completed for bamlanivimab. Participants are no longer being randomized to this intervention.</description>
    <arm_group_label>Bamlanivimab</arm_group_label>
    <other_name>LY3819253</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (IV)</intervention_name>
    <description>Commercially available 0.9% sodium chloride solution.</description>
    <arm_group_label>Placebo (IV)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BRII-196/BRII-198</intervention_name>
    <description>1000 mg (BRII-196)/1000 mg (BRII-198) combination therapy. Administered by consecutive IV infusions as single dose</description>
    <arm_group_label>BRII-196/BRII-198</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AZD7442 (IV)</intervention_name>
    <description>300 mg AZD7442 (150 mg AZD8895 + 150 mg AZD1061). Administered by IV infusion as single dose.</description>
    <arm_group_label>AZD7442 (IV)</arm_group_label>
    <other_name>AZD8895 + AZD1061</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AZD7442 (IM)</intervention_name>
    <description>Administered intramuscularly as 2 separate injections sequentially (300 mg AZD8895 then 300 mg AZD1061) for one dose. Injections administered in the side of the thigh, one injection in each thigh.</description>
    <arm_group_label>AZD7442 (IM)</arm_group_label>
    <other_name>AZD8895 + AZD1061</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SNG001</intervention_name>
    <description>1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device).</description>
    <arm_group_label>SNG001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camostat</intervention_name>
    <description>200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days.</description>
    <arm_group_label>Camostat</arm_group_label>
    <other_name>FOY-305</other_name>
    <other_name>camostat mesilate</other_name>
    <other_name>camostat mesylate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (IM)</intervention_name>
    <description>Commercially available 0.9% sodium chloride Injection, USP. Administered intramuscularly as 2 separate injections, sequentially for one dose. Injections administered in the side of the thigh, one injection in each thigh.</description>
    <arm_group_label>Placebo (IM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Inhaled solution)</intervention_name>
    <description>Trisodium citrate dihydrate, di-sodium hydrogen-phosphate, sodium dihydrogen-phosphate dihydrate, racemic methionine (DL-methionine) and water. 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device).</description>
    <arm_group_label>Placebo (Inhaled solution)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (oral tablet)</intervention_name>
    <description>200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days.</description>
    <arm_group_label>Placebo (oral tablets)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>C135-LS + C144-LS</intervention_name>
    <description>Administered subcutaneously (SC) as 4 separate injections for one dose (two injections of C135-LS 200mg and two injections of C144-SL 200mg).</description>
    <arm_group_label>C135-LS + C144-LS</arm_group_label>
    <other_name>BMS-986414 + BMS-986413</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (SC injections)</intervention_name>
    <description>Administered SC as 4 separate injections for one dose.</description>
    <arm_group_label>Placebo (SC injections)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Documentation of laboratory-confirmed SARS-CoV-2 infection, as determined by a&#xD;
             molecular (nucleic acid) or antigen test from any respiratory tract specimen (e.g.&#xD;
             oropharyngeal, nasopharyngeal (NP), or nasal swab, or saliva) collected ≤240 hours (10&#xD;
             days) prior to study entry and conducted an any US clinic or laboratory that has a&#xD;
             Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent or&#xD;
             any non-US DAIDS-approved laboratory.&#xD;
&#xD;
          -  Able to begin study treatment no later than 8 days from self-reported onset of&#xD;
             COVID-19 related symptom(s) or measured fever, where the first day of symptoms is&#xD;
             considered symptom day 0 and defined by the self-reported date of first reported&#xD;
             sign/symptom from the following list:&#xD;
&#xD;
               -  fever or feeling feverish&#xD;
&#xD;
               -  cough&#xD;
&#xD;
               -  shortness of breath or difficulty breathing at rest or when active&#xD;
&#xD;
               -  sore throat&#xD;
&#xD;
               -  body pain or muscle pain/aches&#xD;
&#xD;
               -  fatigue&#xD;
&#xD;
               -  headache&#xD;
&#xD;
               -  chills&#xD;
&#xD;
               -  blocked nose/nasal congestion&#xD;
&#xD;
               -  runny nose&#xD;
&#xD;
               -  loss of taste or smell&#xD;
&#xD;
               -  nausea or vomiting&#xD;
&#xD;
               -  diarrhea&#xD;
&#xD;
               -  temperature ≥ 38°C (100.4°F)&#xD;
&#xD;
          -  One or more of the following signs/symptoms within 24 hours of participating in the&#xD;
             study:&#xD;
&#xD;
               -  fever or feeling feverish&#xD;
&#xD;
               -  cough&#xD;
&#xD;
               -  shortness of breath or difficulty breathing at rest or when active&#xD;
&#xD;
               -  sore throat&#xD;
&#xD;
               -  body pain or muscle pain/aches&#xD;
&#xD;
               -  fatigue&#xD;
&#xD;
               -  headache&#xD;
&#xD;
               -  chills&#xD;
&#xD;
               -  blocked nose/nasal congestion&#xD;
&#xD;
               -  runny nose&#xD;
&#xD;
               -  loss of taste or smell&#xD;
&#xD;
               -  nausea or vomiting&#xD;
&#xD;
               -  diarrhea&#xD;
&#xD;
               -  temperature ≥ 38°C (100.4°F)&#xD;
&#xD;
          -  Oxygen levels of ≥92% when resting (measured by study staff within 24 hours of&#xD;
             participating in the study). For a potential participant who regularly receives&#xD;
             chronic supplementary oxygen for an underlying lung condition, their oxygen saturation&#xD;
             should be measured while on their standard home oxygen supplementation level.&#xD;
&#xD;
          -  Participant must agree not to participate in another clinical trial for the treatment&#xD;
             of COVID-19 or SARS-CoV-2 during the study period until hospitalization or 28 days&#xD;
             after the start of the study, whichever occurs first.&#xD;
&#xD;
          -  Meet the protocol definition of being at &quot;higher&quot; risk of progression to severe&#xD;
             COVID-19 (BRII-196/BRII-198, AZD7442 [IV]).&#xD;
&#xD;
          -  For participants of reproductive potential, negative serum or urine pregnancy test&#xD;
             within 48 hours prior to study entry by any clinic or laboratory that has a CLIA&#xD;
             certification or its equivalent, or by a point of care (POC)/CLIA-waived test. Note:&#xD;
             Participants not of reproductive potential are eligible without requiring the use of a&#xD;
             contraceptive method (BRII-196/BRII-198. AZD7442 [IV], AZD7442 [IM], SNG001, Camostat,&#xD;
             CL135-LS+C144-LS).&#xD;
&#xD;
          -  Participants that engage in sexual activity that may lead to pregnancy in their&#xD;
             partner must agree to either remain abstinent or use male contraceptives. They are&#xD;
             strongly advised to inform their non-pregnant sexual partners of reproductive&#xD;
             potential to use effective contraceptives for 24 weeks after investigational product&#xD;
             is administered. Participants with pregnant partners should use condoms during vaginal&#xD;
             intercourse through 24 weeks after investigational agent administration. Participants&#xD;
             should refrain from sperm donation for 24 weeks after investigational agent&#xD;
             administration (BRII-196/BRII-198, AZD7442 [IV], AZD7442 [IM]).&#xD;
&#xD;
          -  Participants that engage in sexual activity that may lead to pregnancy in their&#xD;
             partner must agree to either remain abstinent or use male contraceptives for 30 days&#xD;
             after investigational agent administration. They are also strongly advised to inform&#xD;
             their non-pregnant sexual partners of reproductive potential to sue effective&#xD;
             contraceptives for 30 days after investigational agent is administered to the&#xD;
             participant. Participants with pregnant partners should use condoms during vaginal&#xD;
             intercourse through 30 days after last dose of investigational agent administration.&#xD;
             Participants should refrain from sperm donation for 30 days after investigational&#xD;
             agent administration (SNG001).&#xD;
&#xD;
          -  Participants that engage in sexual activity that may lead to pregnancy in their&#xD;
             partner must agree to either remain abstinent or use male contraceptives. They are&#xD;
             also strongly advised to inform their non-regnant sexual partners of reproductive&#xD;
             potential to use effective contraceptives from study entry through 90 days after study&#xD;
             treatment. Participants with pregnant partners should use condoms during vaginal&#xD;
             intercourse from study entry through 90 days after the last dose of the study&#xD;
             treatment. Participants should refrain from sperm donation from study entry through 90&#xD;
             days after the last dose of study treatment (Camostat).&#xD;
&#xD;
          -  If participating in sexual activity that could lead to pregnancy, participants who are&#xD;
             of reproductive potential must agree to use highly effective contraception for 24&#xD;
             weeks after investigational agent is administered (AZD7442 [IV], AZD7442 [IM]).&#xD;
&#xD;
          -  If participating in sexual activity that could lead to pregnancy, participants who are&#xD;
             of reproductive potential must agree to use effective contraception for 30 days after&#xD;
             investigational agent is administered (SNG001).&#xD;
&#xD;
          -  If participating in sexual activity that could lead to pregnancy, participants who are&#xD;
             of reproductive potential must agree to use effective contraception for 90 days after&#xD;
             the last dose of treatment (Camostat).&#xD;
&#xD;
          -  If participating in sexual activity that could lead to pregnancy, participants who are&#xD;
             of reproductive potential must agree to use highly effective contraception for at&#xD;
             least 48 weeks after the investigational agent is administered (C135-LS+C144-LS).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of or current hospitalization for COVID-19.&#xD;
&#xD;
          -  For the current SARS-CoV-2 infection, any positive SARS-CoV-2 molecular test from any&#xD;
             respiratory tract specimen collected more than 10 days prior to study entry.&#xD;
&#xD;
          -  Current need for hospitalization or immediate medical attention.&#xD;
&#xD;
          -  Any use of the following medications up to 30 days before participating in the study:&#xD;
&#xD;
               -  Hydroxychloroquine (except for long-term autoimmune diseases)&#xD;
&#xD;
               -  Chloroquine and/or ivermectin (unless used for parasitic infection)&#xD;
&#xD;
               -  Remdesivir, systemic and inhaled steroids (unless used for long-term conditions)&#xD;
&#xD;
               -  HIV protease inhibitors (unless used long-term for HIV infection)&#xD;
&#xD;
          -  Receipt of convalescent COVID-19 plasma or other antibody-based anti-SARS-CoV-2&#xD;
             treatment or prophylaxis at any time prior to study entry.&#xD;
&#xD;
          -  Receipt of a SARS-CoV-2 vaccine within 6 weeks prior to participating in the study.&#xD;
&#xD;
          -  Receipt of other investigational treatments for SARS-CoV-2 any time before&#xD;
             participating in the study (not including drugs approved and taken for other&#xD;
             conditions/diseases).&#xD;
&#xD;
          -  Known allergy/sensitivity or hypersensitivity to study drug or placebo.&#xD;
&#xD;
          -  Any condition requiring surgery up to 7 days before participating in the study, or&#xD;
             that is considered life threatening up to 30 days before participating in the study.&#xD;
&#xD;
          -  Currently pregnant or breastfeeding (BRII-196/BRII-198, AZD7442 [IV], AZD7442 [IM],&#xD;
             SNG001, Camostat, C135-LS+C144-LS).&#xD;
&#xD;
          -  Inflammatory skin conditions that compromise the safety of intramuscular (IM)&#xD;
             injections, or other overlying skin conditions or tattoos that would preclude the&#xD;
             assessment of injection site reactions, per the discretion of the investigator&#xD;
             (AZD7442 [IM]).&#xD;
&#xD;
          -  Inflammatory skin conditions that compromise the safety of subcutaneous (SC)&#xD;
             injections, or other overlying skin conditions or tattoos that would preclude the&#xD;
             assessment of infection site reactions, per the discretion of the investigator&#xD;
             (C135-LS+C144-LS).&#xD;
&#xD;
          -  History of coagulopathy which, in the opinion of the investigator, would preclude IM&#xD;
             injection, or use of oral or injectable anticoagulants (protocol provides more&#xD;
             information on prohibited medications) (AZD7442 [IM]).&#xD;
&#xD;
          -  Use of or need for chronic supplemental oxygen (SNG001).&#xD;
&#xD;
          -  Known severe liver disease prior to enrollment (defined as ALT or AST &gt; 5 times upper&#xD;
             limit of normal or end stage liver disease with Child-Pugh Class C or&#xD;
             Child-Pugh-Turcotte score ≥ 10) (Camostat).&#xD;
&#xD;
          -  Known severe kidney disease prior to enrollment (defined as estimated glomerular&#xD;
             filtration rate (eGFR) &lt;30 ml/min/1.73m² or on renal-replacement therapy such as&#xD;
             peritoneal dialysis or hemodialysis (Camostat).&#xD;
&#xD;
          -  Meet the protocol definition of being at &quot;higher&quot; risk of progression to sever&#xD;
             COVID-19 (C135-LS+C144-LS).&#xD;
&#xD;
        Other investigational drug protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Smith, MD, MAS</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Research Group (Site 1082), 321 E. 10th Street</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207-5707</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sallie Pulliam</last_name>
      <phone>256-241-6132</phone>
      <email>spulliam@pinnacletrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Alabama Research Center LLC (Site 1194), 721 W. Market St., Ste. B</name>
      <address>
        <city>Athens</city>
        <state>Alabama</state>
        <zip>35611-2456</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Bryant</last_name>
      <phone>256-771-9919</phone>
      <email>dbryant@nhrgi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham (Site 1005), 908 20th Street South</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Olivia Hague</last_name>
      <phone>205-975-4285</phone>
      <email>ohague@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cullman Clinical Trials (Site 1140), 501 Clark St. NE.</name>
      <address>
        <city>Cullman</city>
        <state>Alabama</state>
        <zip>35055-1921</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Hargrove</last_name>
      <phone>256-739-9898</phone>
      <email>Cheryl@cullmanclinicaltrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jasper Summit Research, LLC. (Site 1056), 1280 Summit</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <zip>35501-0102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Sherer</last_name>
      <phone>205-387-7555</phone>
      <phone_ext>Option 3</phone_ext>
      <email>donnas@sleepfirst.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Absolute Clinical Research, LLC. (Site 1186), 7725 North 43rd Avenue, Ste. 211</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia Rodriguez</last_name>
      <phone>623-931-3201</phone>
      <email>l.rodriguez@absoluteclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Arizona (Site 1043), 1501 N. Campbell Ave., Rm. 6410</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Barron</last_name>
      <phone>520-626-8569</phone>
      <email>mbarron@email.arizona.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Franco A. Felizarta MD (Site 1174), 3535 San Dimas St.</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301-1661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecy Felizarta</last_name>
      <phone>661-324-3128</phone>
      <email>cfelizarta@felizartamd.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Jude Heritage Medical Group (Site 1093), 2151 N. Harbor Blvd.</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835-3820</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Diosadado</last_name>
      <phone>714-992-3000</phone>
      <phone_ext>4338</phone_ext>
      <email>maria.diosdado@stjoe.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Diego (Site 1160), 9350 Campus Point Drive, Perlman Cancer Cancer</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandrea Cronin</last_name>
      <phone>619-940-5355</phone>
      <email>aocronin@health.ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fadi A. Haddad, MD, Inc. (Site 1146), 8860 Center Dr., Ste. 320</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942-7001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Somo</last_name>
      <phone>619-376-1904</phone>
      <email>msomo@haddadclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atella Clinical Research (Site 1111), 5451 La Palma Avenue</name>
      <address>
        <city>La Palma</city>
        <state>California</state>
        <zip>90623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yesenia Morales</last_name>
      <phone>714-266-0660</phone>
      <email>ymorales@atellaclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Health (Site 1110), 11374 Mountain View, Dover Bldg, Ste. C</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaclyn Lopez</last_name>
      <phone>909-558-5830</phone>
      <email>janlopez@llu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Southern California (Site 1057), 1300 N. Mission Rd., Rm 349</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-1021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Mendez</last_name>
      <phone>323-409-8283</phone>
      <email>Imendez@usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Center (Site 1003), 11075 Santa Monica Blvd., Suite 100</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Fortier</last_name>
      <phone>310-557-9640</phone>
      <email>sfortier@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Science 37, Inc. (Site 1124), 12121 Bluff Creek Dr., Ste. 100</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90094-2994</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tory Churchill</last_name>
      <phone>424-208-2478</phone>
      <email>tory.churchill@science37.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Northern California Health Care System (NAVREF) (Site 1137), 10535 Hospital Way</name>
      <address>
        <city>Mather</city>
        <state>California</state>
        <zip>95655-4200</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Tran</last_name>
      <phone>916-843-9242</phone>
      <email>michelle.tran@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Valley Research, LLC (Site 1085), 400 E. Orangeburg Ave., Ste. 5</name>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <zip>95350-5365</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haroon Hafeez</last_name>
      <phone>209-918-3344</phone>
      <email>hhafeez@centralvalleyresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valley Clinical Research, Inc. (Site 1059), 18433 Roscoe Blvd., Ste 210</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325-4138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Brown</last_name>
      <phone>818-280-4220</phone>
      <email>monica@valleyclinicaltrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Irvine (Site 1083), 843 Health Sciences Road</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosie Magallon</last_name>
      <phone>949-824-8297</phone>
      <email>rmagallo@hs.uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>FOMAT Medical Research (Site 1136), 300 South A Street</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Martinez</last_name>
      <phone>805-483-1185</phone>
      <email>pmartinez@fomatmedical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eisenhower Medical Center (Site 1040), 39000 Bob Hope Drive</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270-3221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Lane</last_name>
      <phone>760-834-7949</phone>
      <email>llane@eisenhowerhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paradigm Research (Site 1150), 3652 Eureka Way</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001-0172</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Sandberg</last_name>
      <phone>530-247-7049</phone>
      <email>Staylor@paradigm-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center (Site 1097), 2315 Stockton Blvd.</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817-2201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia Smith</last_name>
      <phone>916-734-3339</phone>
      <email>ojsmith@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Premier Urgent Care Centers of California, Inc. (Site 1176), 284 E. Highland Ave.</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Davis</last_name>
      <phone>951-283-3499</phone>
      <email>adaviscrc@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Diego (Site 1002), 220 Dickinson Street</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Hendrickx</last_name>
      <phone>619-543-6968</phone>
      <email>smhendrickx@health.ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zion Medical Center (Site 1063), 4647 Zion Avenue</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Banales</last_name>
      <phone>619-821-5716</phone>
      <email>Diana.b.banales@kp.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA San Diego Health System (Stie 1127), 3350 La Jolla</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161-0002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa St. John</last_name>
      <phone>858-552-8585</phone>
      <phone_ext>2969</phone_ext>
      <email>melissa.st.john@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco (Site 1009), 995 Potrero Ave., Building 80, Ward 84</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Dwyer</last_name>
      <phone>415-476-4082</phone>
      <email>jay.dwyer@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Francisco Research Institute (Site 1210), 2435 Ocean Ave.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94127-2606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymondeep Kaur</last_name>
      <phone>415-745-4340</phone>
      <email>raymondeep@sfinstitute.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University (Site 1213), 1201 Welch Road</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Donahue</last_name>
      <phone>650-725-3515</phone>
      <email>Jdonahu2@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Office of Ramesh V. Nathan, MD (Site 1073), 2220 Lynn Rd., Ste. 301</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360-8005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucinda Van Anglen</last_name>
      <phone>281-295-4106</phone>
      <email>lvananglen@healix.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbor UCLA (Site 1022), 1124 West Carson Street</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Guerrero</last_name>
      <phone>424-201-3000</phone>
      <phone_ext>7318</phone_ext>
      <email>mguerrero@lundquist.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allianz Research Institute Inc. (Site 1159), 14120 Beach Blvd., Ste. 101</name>
      <address>
        <city>Westminster</city>
        <state>California</state>
        <zip>92683-4454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Rodriguez</last_name>
      <phone>714-887-0400</phone>
      <email>silvia.rodriguez@allianzresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado (Site 1007), 12401 East 17th Avenue</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Fiorillo</last_name>
      <phone>303-724-5931</phone>
      <email>Suzanne.Fiorillo@cuanschutz.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UConn - Institute for Collaboration on Health (Site 1169), 2006 Hillside Rd., Unit 1248</name>
      <address>
        <city>Storrs</city>
        <state>Connecticut</state>
        <zip>06269-1248</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Jahne</last_name>
      <phone>860-679-1138</phone>
      <email>jahne@uchc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Whitman-Walker Health (Site 1027), 1337 R Street NW.</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Hoke</last_name>
      <phone>202-797-3589</phone>
      <email>EHoke@whitman-walker.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bradenton Research Center Inc. (Site 1109), 3924 9th Ave. W</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205-1704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Scott</last_name>
      <phone>941-708-0005</phone>
      <email>michellescott@bradentonresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synergy Healthcare (Site 1099), 300 Riverside Drive E., Ste. 1350</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208-1004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Shatz</last_name>
      <phone>941-896-4948</phone>
      <email>mshatz@synergyhealthcorp.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midland Florida Clinical Research Center LLC (Site 1130), 665 Peachwood Drive</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720-0920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey-Ann Villaruel</last_name>
      <phone>386-279-6181</phone>
      <email>staceyann.mfcrc@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universal Axon Clinical Research (Site 1077), 3650 NW 82nd Ave.</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166-6658</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Vega</last_name>
      <phone>305-677-9267</phone>
      <email>rvega@uaclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holy Cross Health (Site 1072), 4725 North Federal Highway</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Gallo</last_name>
      <phone>954-267-6793</phone>
      <email>michelle.gallo@holy-cross.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NW FL Clinical Research Group, LLC. (Site 1046), 400 Gulf Breeze Parkway</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shezsay Colbert</last_name>
      <phone>850-934-1299</phone>
      <email>scolbert@nwflcrg.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indago Research and Health Center (Site 1050), 3700 W. 12th Ave., Ste. 300</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012-4174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Pacheco</last_name>
      <phone>305-825-6588</phone>
      <email>rpacheco@indagoresearch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AGA Clinical Trials (Site 1026), 900 West 49th Street</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Aguirre</last_name>
      <phone>305-819-6990</phone>
      <phone_ext>8004</phone_ext>
      <email>raguirre@agaclinicaltrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Community Research of South Florida (Site 1197), 7100 W. 20th Ave., Ste. 403</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016-1811</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dainerys Canizares</last_name>
      <phone>305-441-6611</phone>
      <email>dcanizares@thecommunityresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Generation Medical Research (Site 1204), 7600 W. 20th Ave., Ste. 106</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016-1895</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Hernandez</last_name>
      <phone>305-828-9100</phone>
      <email>maureenh@ngmresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Innovative Health Medical Center (Site 1222), 6750 Taft Street</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana I Gonzalez</last_name>
      <phone>786-553-3391</phone>
      <email>agonzalez@innovativehealthmd.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida Jacksonville (Site 1039), 655 West 8th Street</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Martins</last_name>
      <phone>904-244-3796</phone>
      <email>mariana.martins@jax.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>QC Trials (Site 1117), 300 W. 41st Street, Ste. 203</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140-3627</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Duke</last_name>
      <phone>786-774-1008</phone>
      <email>christopher@qctrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lakes Research (Site 1037), 5801 NW 151 Street</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yamile Sanchez</last_name>
      <phone>786-362-5763</phone>
      <email>ysanchez@lakesresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Savin Medical Group, LLC. (Site 1212), 5789B NW. 151st Street</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivet Borrego</last_name>
      <phone>305-558-7559</phone>
      <email>iborrego@savinmedicalgroup.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amber Clinical Research, LLC. (Site 1206), 9000 NE. 2nd Avenue</name>
      <address>
        <city>Miami Shores</city>
        <state>Florida</state>
        <zip>33138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvador Fuentes Chamizo</last_name>
      <phone>786-294-0575</phone>
      <email>sfuentes@ambercr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advance Medical Research Center (Site 1193) 330 SW. 27th Ave., Ste. 701</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135-2968</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yenis Barbachan</last_name>
      <phone>786-360-4423</phone>
      <email>barbachanadvance@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>D&amp;H National Research Centers (Site 1205), 8485 Bird Road</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155-3244</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grether Rodriguez</last_name>
      <phone>786-375-6210</phone>
      <email>grdgz@nationalresearchcenters.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allied Biomedical Research Institute (Site 1227), 7100 SW. 47th St., Ste. 220</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155-4630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Estevez</last_name>
      <phone>305-643-8400</phone>
      <email>lestevez@abriusa.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami Clinical Research (Site 1089), 2400 SW. 69th Ave.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yisell Carus</last_name>
      <phone>305-433-6496</phone>
      <phone_ext>409</phone_ext>
      <email>ycarus@miamiclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>RM Medical Research, Inc. (Site 1230), 10346 W. Flagler St.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33174-1746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Sanchez</last_name>
      <phone>786-600-0012</phone>
      <email>lsanchez@rmmedicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pro Live Medical Research Corp (Site 1219), 12781 SW. 42nd Street</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175-3437</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Medina</last_name>
      <phone>305-221-8001</phone>
      <email>mmedina@prolivemed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center (Site 1045), 1707 North Mills Avenue</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Hirsch</last_name>
      <phone>407-647-3960</phone>
      <email>mhirsch@oicorlando.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clintheory (Site 1203), 7350 Sandlake Commons Blvd.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meily Sieiro</last_name>
      <phone>407-698-3424</phone>
      <email>Msieiro@clintheory.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IMIC, Inc. (Site 1141), 18320 Franjo Rd</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157-5503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Tijerino</last_name>
      <phone>786-310-7477</phone>
      <email>adriana@aktamedika.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Family Clinical Trials (Site 1236), 1601 N. Palm Ave., Ste. 102</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026-3240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisbel Gonzelez</last_name>
      <phone>954-842-3147</phone>
      <email>lgonzalez@familyclinicaltrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ETNA Medical Center (Site 1225), 7401 N. University Drive</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Martinez</last_name>
      <phone>954-573-6381</phone>
      <email>fmartinez@etnamedicalcenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moore Clinical Research, Inc. (Site 1164), 4257 W. Kennedy Blvd.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609-2230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Juneja</last_name>
      <phone>813-948-7550</phone>
      <phone_ext>402</phone_ext>
      <email>ejuneja@moorecr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital Family Care Center Healthpark (Site 1088), 5802 N. 30th Street</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33610-1469</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyle Cesareo</last_name>
      <phone>919-390-8457</phone>
      <email>kcesareo@usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Consultants of the Treasure Coast (Site 1171), 3735 11th Cir., Ste. 201</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960-4889</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Van Cleave</last_name>
      <phone>772-299-7009</phone>
      <phone_ext>102</phone_ext>
      <email>natalie@idctc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AIDS Research and Treatment Center of the Treasure Coast (Site 1095), 981 37th Place</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mona White</last_name>
      <phone>772-978-9556</phone>
      <phone_ext>280</phone_ext>
      <email>mwhite@verotcid.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute PA (Site 1121), 2580 Metrocentre Blvd., Ste. 4</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407-3100</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Praewpailin Rich</last_name>
      <phone>561-855-7871</phone>
      <email>prich@tripleoresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ponce de Leon Center (site 1015), 341 Ponce De Leon Avenue Northeast</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ericka Patrick</last_name>
      <phone>404-616-6313</phone>
      <email>erpatri@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Agile Clinical Rsearch Trials, LLC (Site 1051), 750 Hammond Drive</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shauna Marshall</last_name>
      <phone>770-573-4109</phone>
      <email>marshall@agilecrt.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IACT Health (Site 1035), 800 Talbotton Road</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Cutts</last_name>
      <phone>706-321-0495</phone>
      <email>jcutts@iachealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renew Health Clinical Research, LLC. (Site 1161), 1550 Janmar Rd.</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078-5779</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kalpana Soni</last_name>
      <phone>502-807-9128</phone>
      <email>Kalpana.soni@renewhealthcr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Snake River Research, PLLC (Site 1120), 2900 Cortez Ave.</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404-7554</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Morrison</last_name>
      <phone>208-535-8404</phone>
      <email>jmorrison@snakerr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Metro Infectious Disease Consultants (Site 1106), 901 McClintock Dr., Ste. 201</name>
      <address>
        <city>Burr Ridge</city>
        <state>Illinois</state>
        <zip>60527-0872</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Van Hise</last_name>
      <phone>630-655-6952</phone>
      <email>nvanhise@innovativeventures.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chicago Clinical Research Institute (Site 1132), 611 W. Roosevelt Rd.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607-4911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jovita Rodrigues</last_name>
      <phone>312-791-3241</phone>
      <email>jovita@ccrii.us</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University (Site 1025), 645 North Michigan Ave</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baiba Berzins</last_name>
      <phone>312-695-5012</phone>
      <email>baiba@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center (Site 1017), 600 Paulina St.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Swiatek</last_name>
      <phone>312-942-6017</phone>
      <email>Joan_Swiatek@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago (Site 1064), 5841 S. Maryland Ave.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1443</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Stetkevych</last_name>
      <phone>773-702-1665</phone>
      <email>jstetkevych@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials (Site 1049), 5149 N. Ashland Ave.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640-2831</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Holst</last_name>
      <phone>773-275-3500</phone>
      <email>aholst@greatlakesclinicaltrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roudebush VA Medical Center (Site 1217), 550 University Blvd</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5149</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandra Radovanovich</last_name>
      <phone>317-988-3338</phone>
      <email>Aleksandra.Radovanovich@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center (Site 1042), 3901 Rainbow Boulevard</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Boccardi</last_name>
      <phone>913-588-4022</phone>
      <email>lboccardi@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedPharmics (Site 1065), 3800 Houma Blvd.</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Guttierrez</last_name>
      <phone>504-304-7083</phone>
      <email>nicoleguttierrez@medpharmics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Orleans Adolescent Trials Unit (Site 1028), 1440 Canal St., Suite 904</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112-2703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Callegari</last_name>
      <phone>504-988-1467</phone>
      <email>ecallegari@tulane.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center (Site 1153), 2000 Canal Street</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112-3018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Weiser</last_name>
      <phone>504-568-7740</phone>
      <email>sweise@lsuhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University (Site 1006), 1830 East Monument Street</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Becker</last_name>
      <phone>410-614-4036</phone>
      <email>Rbecke22@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Walter Reed Army Institute of Research (Site 1118), 503 Robert Grant Ave.</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910-7500</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Sanborn</last_name>
      <phone>301-319-3386</phone>
      <email>aaron.d.sanborn.mil@mail.mil</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital (Site 1016), 55 Fruit Street</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Flynn</last_name>
      <phone>617-724-0072</phone>
      <email>tflynn@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital - Therapeutics Clinical Research Site (Site 1023), 75 Francis Street</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria McRae</last_name>
      <phone>617-525-7922</phone>
      <email>mmcrae@bwh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School (Site 1054), 55 Lake Avenue N.</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655-0002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shestruma Parajuli</last_name>
      <phone>508-856-5010</phone>
      <email>shestruma.parajuli@umassmed.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital at Gulfport (Site 1104), 4500 13th Street</name>
      <address>
        <city>Gulfport</city>
        <state>Mississippi</state>
        <zip>39501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristian Spear</last_name>
      <phone>228-365-9516</phone>
      <email>kspear@mhg.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedPharmics, LLC. (Site 1032), 15190 Community Rd.</name>
      <address>
        <city>Gulfport</city>
        <state>Mississippi</state>
        <zip>39503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Hill</last_name>
      <phone>228-206-1283</phone>
      <phone_ext>201</phone_ext>
      <email>meganhill@medpharmics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hannibal Clinic (Site 1129), 100 Medical Drive</name>
      <address>
        <city>Hannibal</city>
        <state>Missouri</state>
        <zip>63401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimber Steinbeck</last_name>
      <phone>573-231-3261</phone>
      <email>ksteinbeck@hannibalclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine (Site 1008), 620 South Taylor, Suite 200</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Kessels</last_name>
      <phone>314-747-1096</phone>
      <email>lkessels@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bozeman Health Deaconess Hospital (Site 1115), 931 Highland Blvd, Ste. 3103</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59715-6911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Gott</last_name>
      <phone>406-414-3745</phone>
      <email>agott@bozemanhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercury Street Medical Group (Site 1074), 300 W. Mercury St.</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701-1652</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Harvey</last_name>
      <phone>406-723-1375</phone>
      <email>michelle.violette@mercurystmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research (Site 1112), 10040 Regency Circle</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Larsen</last_name>
      <phone>402-934-0044</phone>
      <email>jenny@qcromaha.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Las Vegas Medical Research (Site 1048), 8530 W. Sunset Rd.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113-2215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Martinez</last_name>
      <phone>702-750-0222</phone>
      <email>tinam@lvmedresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lincoln Hospital (Site 1092), 249 East 149th Street</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maryanne Guerrero</last_name>
      <phone>718-579-6067</phone>
      <email>maryanne.guerrero@nychhc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center (Site 1105), 1400 Pelham Parkway South</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Diaz</last_name>
      <phone>718-918-5349</phone>
      <email>olga.diaz@nbhn.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>James J. Peters VA Medical Center (Site 1053), 130 West Kingsbridge Road</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zarema Jagizarov</last_name>
      <phone>718-584-9000</phone>
      <phone_ext>5776</phone_ext>
      <email>Zarema.jagizarov@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maimonides Medical Center (Site 1138), 4802 10th Avenue</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219-2916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rukhsana Hossain</last_name>
      <phone>718-283-6076</phone>
      <email>RHossain@maimonidesmed.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University at Buffalo, Emergency Medicine (Site 1172), 77 Goodell Street</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy Connery</last_name>
      <phone>716-675-9705</phone>
      <email>lucy.connery@daemen.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Flushing Hospital Medical Center (Site 1067), 4500 Parsons Blvd</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355-2205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Cervellione</last_name>
      <phone>718-670-3012</phone>
      <email>kcervell@jhmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jamaica Hospital Medical Center (Site 1066), 8900 Van Wyck Expressway</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11418-2832</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tofura Ullah</last_name>
      <phone>718-206-5828</phone>
      <email>tullah@jhmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia Partnership for Prevention and Control of HIV/AIDS CTU (Site 1019), Columbia University Irving Medical Center, Department of Medicine - Division of Infectious Diseases, 180 Fort Washington Avenue, HP6 - Rm 604</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret Gray</last_name>
      <phone>212-305-1570</phone>
      <email>bg2168@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cornell Clinical Trials Unit (Site 1011), NewYork-Presbyterian Hospital-Weill Cornell Medical Center, 525 East 68th Street</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valery Hughes</last_name>
      <phone>646-246-8327</phone>
      <email>vah9001@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Canton-Potsdam Hospital (Site 1076), 50 Leroy Street</name>
      <address>
        <city>Potsdam</city>
        <state>New York</state>
        <zip>13676-1786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Jaremczuk</last_name>
      <phone>315-261-6013</phone>
      <email>djaremczuk@cphospital.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester (Site 1010), 601 Elmwood Ave</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Hurley</last_name>
      <phone>585-273-5636</phone>
      <email>christine_hurley@urmc.rochester.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Stony Brook NICHD (Site 1094), HSC L-02, Rm. 142 C</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barsha Chakraborty</last_name>
      <phone>631-444-7692</phone>
      <email>barsha.chakraborty@stonybrookmedicine.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill (Site 1001), 130 Mason Farm Rd., Bioinformatics Bldg, 2nd Floor</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Straub</last_name>
      <phone>919-843-9975</phone>
      <email>becky_straub@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina Clinical Research (Site 1167), 9040 Nations Ford Rd.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>38273-5716</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abigail Nicholson</last_name>
      <phone>704-290-4587</phone>
      <email>anicholson@carolinaclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center (Site 1041), 40 Duke Medicine Circle</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Gazda</last_name>
      <phone>570-817-0226</phone>
      <email>stephen.gazda@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences (Site 1038), 1 Medical Center Boulevard</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Zieser-Misenheimer</last_name>
      <phone>336-716-5685</phone>
      <email>ezieserm@wakehealth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanford Health (Site 1084), 801 Broadway N.</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58102-3641</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Breanna Kompelien</last_name>
      <phone>701-234-6063</phone>
      <email>breanna.kompelien@sanfordhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital (Site 1119), 2123 Auburn Avenue</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxanne Robertson</last_name>
      <phone>513-585-1777</phone>
      <email>roxanne.robertson@thechristhospital.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University (Site 1033), 2061 Cornell Road</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5083</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Baum</last_name>
      <phone>216-844-2546</phone>
      <email>baum.jane@clevelandactu.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center (Site 1195), 2500 Metrohealth Dr.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109-1900</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine Russ</last_name>
      <phone>216-778-5278</phone>
      <email>kruss@metrohealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center (Site 1020), 480 Medical Center Drive</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Watson</last_name>
      <phone>614-293-8112</phone>
      <email>kathy.watson@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati CRS (Site 1004), University of Cincinnati, University Hospital, 200 Albert Sabin Way</name>
      <address>
        <city>Ohio City</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Kohrs</last_name>
      <phone>513-584-6383</phone>
      <email>kohrssd@ucmail.uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>STAT Research (Site 1107), 66 Remick Blvd.</name>
      <address>
        <city>Springboro</city>
        <state>Ohio</state>
        <zip>45066-9168</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Heffner</last_name>
      <phone>937-223-4229</phone>
      <email>Megan@statresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ascension St. John Clinical Research Institute (Site 1090), 1725 East 19th Street</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacie Merritt</last_name>
      <phone>918-744-3426</phone>
      <email>stacie.merritt@ascension.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Center for Health Research (Site 1079), 3800 N. Interstate Ave.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227-1110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Mularski</last_name>
      <phone>503-335-2420</phone>
      <email>ACTIV2study@kpchr.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Doylestown Hospital (Site 1122), 595 W. State Street</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901-2554</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Mannion</last_name>
      <phone>215-345-2842</phone>
      <email>tmannion@dh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania (Site 1031), 3400 Spruce Street</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miranda Mastellone</last_name>
      <phone>267-819-8608</phone>
      <email>miranda.mastellone@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Pittsburgh (Site 1018), 3471 5th Ave.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-3215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Weinman</last_name>
      <phone>412-383-1748</phone>
      <email>drw38@pitt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Pittsburgh Healthcare System (Site 1070), University Drive C.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Gilbert</last_name>
      <phone>412-360-6666</phone>
      <email>karen.gilbert2@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital Clinical Research Site (1142), 164 Summit Avenue</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Patterson</last_name>
      <phone>401-793-4771</phone>
      <email>hpatterson@lifespan.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medtrial, LLC (Site 1134), 1718 Saint Julian Pl., Ste. 2</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204-2410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaushlendra Tripathi</last_name>
      <phone>803-254-4295</phone>
      <email>kt@medtrialsc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>American Indian Clinical Trials Research Network (Site 1148), 717 Meade Street</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norma Jo Tibbits</last_name>
      <phone>605-939-3686</phone>
      <email>njtibbits@bhcaih.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanford USD Medical Center (Site 1078), 1305 W. 18th St.</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105-0401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Onnen</last_name>
      <phone>605-328-1374</phone>
      <email>sara.onnen@sanfordhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Center of Middle Tennessee (Site 1183), 100 Covey Drive</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Wallan</last_name>
      <phone>615-205-8350</phone>
      <email>jwallan@ctcmidtn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Therapeutics Clinical Research (Site 1013), Vanderbilt Health One Hundred Oaks, 719 Thompson Ln., Ste 47183</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204-4718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly Woddward</last_name>
      <phone>615-936-8516</phone>
      <email>beverly.o.woodward@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Hope Foundation Inc. (Site 1100), 6800 West Loop Street, Ste. 560</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401-4516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Degazon</last_name>
      <phone>832-494-1253</phone>
      <email>shfkenneth1@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PanAmerican Clinical Research, LLC. (Site 1069), 1416 Palm Blvd.</name>
      <address>
        <city>Brownsville</city>
        <state>Texas</state>
        <zip>78520-7256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Enrique Magana</last_name>
      <phone>956-357-0984</phone>
      <email>lmagana@panamclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trinity Health and Wellness Center (Site 1030), 219 Sunset Avenue</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Rogers</last_name>
      <phone>972-807-7370</phone>
      <email>lauren.rogers@prismntx.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Doctors Hospital at Renaissance Health Institute for Research and Development (Site 1145), 5323 S. McColl Rd.</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Martinez</last_name>
      <phone>956-362-2377</phone>
      <email>va.martinez@dhr-rgv.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sealy Institute for Vaccine Sciences Clincial Trials Program (Site 1044), 400 Harborside Drive</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerianne Casey</last_name>
      <phone>409-772-5278</phone>
      <email>gecasey@utmb.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyndon B. Johnson Hospital (Site 1014), 5656 Kelley Street</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77026-1967</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damian A Chiandussi</last_name>
      <phone>713-500-5512</phone>
      <email>damian.a.chiandussi@uth.tmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston (Site 1055), 6431 Fannin Street, Ste. 2.112</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-1501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehriban Mammadova</last_name>
      <phone>713-500-6761</phone>
      <email>mehriban.mammadova@uth.tmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital (Site 1123), 6565 Fannin Street</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Bonmati</last_name>
      <phone>713-441-3879</phone>
      <email>ambonmati@houstonmethodist.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dynamic Medical Research Group (Site 1081), 8314 Southwest Fwy</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074-1603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chioma Uzor</last_name>
      <phone>832-308-8851</phone>
      <email>clinicaltrials@dynamicmedresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fairway Medical Clinic (Site 1156), 4910 Telephone Road</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77087</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abid Ahsan</last_name>
      <phone>281-944-3610</phone>
      <email>Abid@biopharmainfo.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SMS Clincial Research, LLC. (Site 1060), 1210 N. Galloway Ave.</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75149-2438</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prisilla Fajardo</last_name>
      <phone>972-216-5152</phone>
      <email>pfajardo@smsclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Epic Medical Research, LLC (Site 1233), 106 Plaza Drive</name>
      <address>
        <city>Red Oak</city>
        <state>Texas</state>
        <zip>75154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josie Quemado</last_name>
      <phone>972-777-6956</phone>
      <email>jquemado@epicmedresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Medical Campus (Site 1029), 3300 Gallows Road</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042-3307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>IHVI Research Team</last_name>
      <phone>703-776-7699</phone>
      <email>ihviresearch@inova.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Partners LLC (Site 1196), 7110 Forest Ave., Ste. 201</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226-3787</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Craighead</last_name>
      <phone>804-477-3045</phone>
      <email>kc@clinicalresearchrva.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>EvergreenHealth (Site 1080), 12040 NE 128th Street, Ste MS-77</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034-3013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Mufrej</last_name>
      <phone>452-899-5362</phone>
      <email>aamufrej@evergreenhealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington ACTU (Site 1012), Harborview Medical Center, 325 9th Ave.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Jonsson</last_name>
      <phone>206-744-8886</phone>
      <email>cjonsson@uw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Medical Research Center (Site 1075), 105 W. 8th Ave., Ste. 6050W</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204-2312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carissa Urbat</last_name>
      <phone>509-474-3820</phone>
      <email>carissa.urbat@providence.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hershel Woody Williams VA Medical Center (Site 1128), 1540 Spring Valley Drive</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Damron</last_name>
      <phone>304-429-6741</phone>
      <phone_ext>3803</phone_ext>
      <email>alexis.damron@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West VA University, Mary Babb Randolph Cancer Center (Site 1178), 1 Medical Center Drive</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506-1200</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Loudin</last_name>
      <phone>304-293-6066</phone>
      <email>sabrina.martinvernon@hsc.wvu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin, Inc. (Site 1036), 8701 Watertown Plank Road</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonija Parker</last_name>
      <phone>414-955-0492</phone>
      <email>smparker@mcw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allegiance Research Specialists (Site 1162), 2645 N. Mayfair Rd., Ste. 200</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226-1304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Vogen</last_name>
      <phone>414-727-8131</phone>
      <email>vogen@arsmke.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Puerto Rico AIDS Clinical Trials Unit (Site 1024), Proyecto ACTU Biomedical Building II</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marielly López-Rivera</last_name>
      <phone>787-767-9192</phone>
      <email>marielly.lopez@upr.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>https://www.cdc.gov/coronavirus/2019-nCoV/index.html</url>
    <description>CDC (Centers for Disease Control and Prevention): Coronavirus (COVID-19) website</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/clinical-trials/participant-guide</url>
    <description>A Participant's Guide to Clinical Trials (NIAID)</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/clinical-trials/find-a-clinical-trial</url>
    <description>Find a Clinical Trial (NIAID)</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/clinical-trials</url>
    <description>Clinical Trials at NIAID</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute for Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>https://www.covid19treatmentguidelines.nih.gov/</url>
    <description>NIH COVID-19 treatment guidelines</description>
  </link>
  <link>
    <url>https://www.who.int/emergencies/diseases/novel-coronavirus-2019/</url>
    <description>WHO COVID-19 treatment guidelines</description>
  </link>
  <link>
    <url>https://www.nih.gov/research-training/medical-research-initiatives/activ</url>
    <description>NIH: Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>COVID 19</keyword>
  <keyword>Coronaviridae Infections</keyword>
  <keyword>Coronavirus Infections</keyword>
  <keyword>RNA Virus Infections</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Nidovirales Infections</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>SARS Coronavirus</keyword>
  <keyword>ACTIV-2</keyword>
  <keyword>ACTIV2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabexate</mesh_term>
    <mesh_term>Camostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form: Main ICF</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 8, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT04518410/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Multiple Study Drugs ICF</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 8, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT04518410/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Optional Extra Samples ICF</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 8, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT04518410/ICF_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Study Drug LY3819253 (Bamlanivimab) ICF</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 8, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT04518410/ICF_003.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

